Evidence map›Paper›PMID 41876605›Full record

ArticleScientific reports2026

Mathematical modeling of sequential Dengue-Zika infections: dynamic insights into antibody-dependent enhancement and neutralization effects.

Preeti Deolia, Anuraj Singh, Anuj Mubayi

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Preeti DeoliaNational Disease Modeling Consortium, Indian Institute of Technology Bombay, Mumbai, Maharashtra, India.
Anuraj SinghDepartment of Engineering Sciences, ABV-Indian Institute of Information Technology and Management Gwalior, Gwalior, Madhya Pradesh, India. anuraj@iiitm.ac.in.
Anuj MubayiIntercollegiate Biomathematics Alliance, Normal, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human infections caused by viruses of the Flavivirus genus, such as dengue virus and Zika virus, are developing global concern. The phenomenon of antibody-dependent enhancement (ADE) indicates that secondary infection with one flavivirus after a primary infection with another can lead to a larger viral load. This poses challenges for existing dengue vaccines and presents obstacles to the development of future Zika vaccines. This study aims to shed light on a distinct aspect of ADE, known as antibody-dependent neutralization (ADN). A sequential infection model for dengue and Zika is proposed, capturing the joint dynamics of both diseases. A qualitative analysis is conducted, examining a disease-free state and four boundary equilibrium points, with two strains representing sequential dengue and Zika infections. The model is calibrated using weekly case data on dengue and Zika infections from Espirito Santo, Brazil, from January 3, 2021, to September 11, 2021. To identify the key drivers of disease dynamics, we apply global sensitivity analysis techniques, including partial rank correlation coefficient (PRCC) and Latin hypercube sampling (LHS). Analysis reveals that although ADE has an obstructive impact on sequential cases, it can contribute to neutralizing infection status when it exceeds a threshold due to ADN.

Indexed as

Antibodies, NeutralizingAntibody-Dependent EnhancementDengueModels, TheoreticalZika VirusZika Virus InfectionAntibodies, ViralBrazilDengue VirusHumansAntibodies, NeutralizingAntibodies, ViralAntibody-dependent enhancementAntibody-dependent neutralizationDengue–Zika sequential infectionGlobal stabilityPRCC analysis

Identifiers

PMID41876605
PMCPMC13168338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.